Treatment of heart failure in patients with diabetes: Clinical update

Ethnicity and Disease

Volumn 12, Issue 1, 2002, Pages

  Bell, David S H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CAPTOPRIL; CARVEDILOL; DICHLOROACETIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; KIDNEY RENIN; LISINOPRIL; METOPROLOL; NORADRENALIN; PYRUVATE DEHYDROGENASE; TRIACYLGLYCEROL; TROGLITAZONE; ANTIDIABETIC AGENT; CARDIOTONIC AGENT;

ADRENERGIC TRANSMISSION; ARTICLE; CARBOHYDRATE METABOLISM; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; METABOLIC DISORDER; MORTALITY; PREVALENCE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT PLANNING; VASOCONSTRICTION; CONGESTIVE HEART FAILURE; DRUG INTERACTION; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

BLOOD GLUCOSE; CARDIOTONIC AGENTS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036244244     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Diabetes and cardiovascular disease
2. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus
3. Congestive heart failure in type 2 diabetes: Prevalence, incidence and risk factors
4. Frequency of diabetes among patients admitted to hospital because of congestive heart disease
5. Treatment of patients admitted to the hospital with congestive heart failure: Specialty-related disparities in practice patterns and outcomes
6. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
7. Effects of enalapril on mortality in severe congestive heart failure
8. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
9. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
10. Increased insulin and glucose levels in heart failure (HF)
11. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study
12. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction
13. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
14. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year
15. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria
16. Natural history and patterns of current practice in heart failure
17. Pre-clinical abnormality of left ventricular function in diabetes mellitus
18. Introduction and overview: Beta-blocker therapy in the management of chronic heart failure
19. Sudden death prevention in patients with advanced ventricular dysfunction
20. Biochemical detection of left-ventricular systolic dysfunction
21. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease?
22. Microangiopathy and focal myocardial injury: Their role in the development of diabetic cardiomyopathy
23. Clinical studies on diabetic myocardial disease using exercise testing with myocardial scintigraphy and endomyocardial biopsy
24. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure
25. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure
26. Human coronary microvessels in diabetes and ischemia. Morphometric study of autopsy material
27. Why does the myocardium fail? Insights from basic science
28. Effects of glucose and fatty acids on myocardial ischemia and arrhythmias
29. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs
30. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate
31. Lipotoxic heart disease in obese rats: Implications for human obesity
32. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
33. Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk)
34. Ischemic cardiomyopathy and the cellular renin-angiotensin system
35. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats
36. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system
37. Left ventricular remodeling in the year after first anterior myocardial infarction: A quantitative analysis of contractile segment lengths and ventricular shape
38. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry
39. Uniformity of captopril benefit in the SAVE Study: Subgroup analysis. Survival and Ventricular Enlargement Study
40. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: Data from the GISSI-3 study
41. Adrenergic effects on the biology of the adult mammalian cardiocyte
42. Heart rate in relation to insulin sensitivity and insulin secretion in nondiabetic subjects
43. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma
44. Cardiac beta-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury. Evidence for catecholamine-mediated myocardial damage
45. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure
46. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with beta-adrenergic blockade
47. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
48. Beta adrenergic blocking agents in patients with diabetes-friend and foe
49. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial
50. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: The carvedilol-metoprolol study
51. Glucose clamp technique: A method for quantifying insulin secretion and resistance